Skip to main content

Table 3 Patient distribution by NCCN HR and VHR risk groups and 4 year b-DFS, MFS, CSS and OS

From: Classifying high-risk versus very high-risk prostate cancer: is it relevant to outcomes of conformal radiotherapy and androgen deprivation?

 

2014

2014+>2 HR

2015

2015+>2 HR

HR

VHR

HR

VHR

HR

VHR

HR

VHR

N

166

37

131

72

100

103

65

138

%

82%

18%

64.5%

35.5%

49%

51%

32%

68%

4y bDFS % (95% CI)

89 (82–93)

83 (66–92)

89 (82–93)

84 (73–91)

90 (82–95)

85 (75–91)

92 (80–97)

85 (78–90)

4y MFS % (95% CI)

90 (84–94)

83 (63–93)

92 (84–96)

85 (72–92)

93 (85–97)

85 (75–92)

93 (78–98)

87 (80–92)

4y CSS % (95% CI)

100

92 (70–98)

100

95 (82–99)

100

97 (88–99)

100

98 (91–99)

4y OS % (95% CI)

96 (92–99)

85 (64–94)

98 (93–100)

87 (74–94)

96 (89–99)

92 (83–96)

100

91 (84–96)

  1. HR = High Risk, VHR = Very High Risk, b-DFS = biochemical disease free survival, MFS = metastasis free survival, CSS = cause specific survival, OS = overall survival
  2. NCCN 2014 HR= Stage: T3a, Gleason: 8–10, PSA>20, VHR= T3B, T4
  3. NCCN 2015 HR= Stage: T3a, Gleason: 8–10, PSA>20, T3b-T4, Primary Gl 5, >4 cores with Gl 8–10